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1. Introduction
Alcohol consumption is linked to a large number of health
impairments, chronic diseases and deaths worldwide [1]. The
2012 Monograph of the International Agency for Research on
Cancer (IARC) provides stronger evidence on the carcinogenicity of
alcohol by tumour sites and by mechanisms of alcohol carcino-
genesis even for low and moderate alcohol intakes [2,3]. The IARC
Monographs reached the conclusion: ‘‘alcohol consumption is
carcinogenic to humans (Group 1); ethanol in alcoholic beverages
is carcinogenic to humans (Group 1); acetaldehyde associatedwith
the consumption of alcoholic beverages is carcinogenic to humans
(Group 1)’’ [2]. Overall, there is no consistent difference in cancer
risk between different types of alcoholic beverage [4–6]. Europe is
the region of highest alcohol consumption in the world, with an
average consumption of more than twice the global average; it has
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A B S T R A C T
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International Agency for Research on Cancer (IARC)Monographs provide strengthened evidence that the
consumption of alcoholic beverages is causally associated with cancers of the oral cavity, pharynx,
larynx, oesophagus, liver, colorectum and female breast, even for low and moderate alcohol intakes. The
risk of cancer increases in a dose-dependent manner, and the higher the amount of alcohol consumed,
the higher the risk of developing cancer. Several biological mechanisms explain the carcinogenicity of
alcohol; among them, ethanol and its genotoxic metabolite acetaldehyde play a major role. Taking all
this evidence into account, a recommendation of the 4th edition of the European Code against Cancer
(ECAC) is: ‘‘If you drink alcohol of any type, limit your intake. Not drinking alcohol is better for cancer
prevention.’’
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a high prevalence of hazardous drinkers and an average alcohol-
attributable cancer burden which also exceeds by far the global
average [1]. Taken together, the 4th edition of the European Code
Against Cancer (ECAC) [7] advocates action-oriented recommen-
dations for the general public. The ECAC recommends decreasing
or cutting alcohol consumption in order to prevent several types of
cancer and to improve overall health.
1.1. European alcohol consumption among adult and young
generations
Per capita alcohol consumption has been falling in the European
Union (EU) as awhole over the past three decades, while remaining
particularly high compared to the global average. The most recent
sales data show that individuals aged 15 years drink on average
10.7 l of pure alcohol per year [8]. Consumption tends to be higher
in the Central-Eastern and Eastern countries such as, for example,
Latvia, Romania, Lithuania and Austria, all of which have an
average consumption >12 l per capita. At the other end of the
spectrum, Mediterranean countries (e.g., Italy, Malta and Greece)
and Nordic Countries (e.g., Norway, Sweden and Iceland) have
relatively lower levels of consumption, in the region of 7–8 l of
pure alcohol per adult person (Fig. 1). Gender, age and socio-
economic status are key factors in determining levels of alcohol
consumption [9]. Men are more likely to consume alcohol than
women, and to drink more when they do [10], particularly in
Central, Western and Northern EU countries. Compared to older
adults, young and middle-aged people tend to drink higher
volumes of alcohol [11]. Women with higher level of education
tend to drink more alcohol while the opposite is generally true for
men [10]. Hazardous drinking behaviours, such as binge drinking
(i.e., the occasional consumption of 60 g of pure alcohol on the
same occasion and at least one day in the last month), have been
increasing over the past 20 years [13], especially in Germany and
Ireland and among younger generations [14–17]. The prevalence of
binge drinkers doubled in France and has increased by about 30% in
Germany between 2002 and 2008 [13]; binge drinking was
reported by 36% of girls and 40% of boys in 2010 [8].
1.2. Effect of alcohol drinking on coronary heart disease
Light to moderate alcohol consumption might be associated
with a reduced risk of coronary heart disease. A small reduction in
risk has been suggested for the consumption of one drink every
second day (not including as ‘abstainers’ those who reduced or
stopped drinking [18]), and is probably conﬁned tomiddle-aged or
older individuals [18–20]. Similarly, a recent systematic review
suggests that light to moderate alcohol consumption might be
associated with a reduced risk of cardiovascular outcome, in
particular coronary heart disease mortality compared to stroke
[21], but again reverse causation and residual confounding cannot
be excluded. While there is some evidence that low doses of
alcohol may raise blood levels of high-density lipoprotein and
improve reduction in coagulation [22,23], high doses may
precipitate cardiac arrhythmias, myocardial ischaemia or infarc-
tion, and coronary death [24–26].
2. Association with cancer
2.1. Cancer types associated with alcohol drinking
As established by the IARC Monographs, consumption of
alcoholic beverages is causally associated with cancers of the oral
cavity, pharynx, larynx, oesophagus, colorectum, liver (hepatocel-
lular carcinoma), and female breast in a dose-dependent manner
[2]. Summary relative risks (RR) supporting these associations both
for light and heavy drinking are indicated in Table 1. The
relationship between alcohol consumption and cancer risk is
monotonic and without a threshold (Fig. 2). Alcohol consumption
accounts for about 3% and 10% of total cancers diagnosed inwomen
and men, respectively [27]. In both genders, the alcohol-attribut-
able fraction is high for upper aero-digestive tract (25–44%), liver
(18–33%), and colorectal (4–17%) cancers, and in women for breast
cancer (about 5%), with variation across EU countries related to
different levels of exposure to alcohol [27]. Drinking patterns play
an important role in modulating the relationship between alcohol
and cancer risk. The strongest associations are observed for heavy
drinking, in particular regular heavy drinking. Any reduction in
alcohol consumption has a beneﬁcial effect on reducing the risk of
cancer.
2.1.1. Neoplasms of the upper digestive tract: oral cavity, pharynx,
larynx and squamous-cell carcinoma of the oesophagus
Results from cohort studies and recent meta-analyses provide
convincing evidence that the consumption of alcoholic beverages
increases the risk of neoplasms of the upper digestive and
respiratory tracts (UADT) even in the absence of smoking.
Signiﬁcant dose–response relationships are found with different
[(Fig._1)TD$FIG]
Fig. 1. Average European adult alcohol consumption in litres/capita/year among populations aged15 years (years 2010 and 1980). From calculations provided by the OECD
based on ‘‘Health at a glance: Europe 2012. OECD Publishing, 2012’’ [8].
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metrics of exposure to alcohol such as level, frequency [28] and
duration [29] of consumption, and for moderate intake in women
[4,30,31]. Among non-smokers, reported RRs for oesophageal
squamous-cell carcinoma and laryngeal cancer range from 0.74
(95%CI: 0.47–1.16) for light intakes to 3.09 (95%CI: 1.75–5.46) for
high intakes [31,32]. Risks for oropharyngeal cancer are as high as
5.40 (95%CI: 4.49–6.50) [33]. The combined exposure to alcohol
drinking and tobacco smoking results in a supra-multiplicative
synergistic effect which enhances the risk of these neoplasms up to
14-fold, among heavy smokers and heavy drinkers (four or more
drinks/day) [34,35] (Fig. 3).
There is evidence that the risk of UADT cancer decreases with
time since drinking cessation, without however ever falling to that
of lifetime abstainers. A recentmeta-analysis reports an average 2%
decreased risk of pharyngeal and laryngeal cancers per year of
cessation [36]. A trend for decreased risk is suggested for laryngeal,
oropharyngeal and oesophageal cancers among former drinkers.
After at least 6 years of drinking cessation, odds ratios decreased to
1.24 (95%CI: 0.68–2.47) [37], 1.74 (95%CI: 0.77–3.92) [38], and 0.85
(95%CI: 0.78–0.92) for laryngeal, oropharyngeal and oesophageal
cancers, respectively [39,40].
2.1.2. Neoplasms of the lower digestive tract: colorectum and liver
Results from cohort studies and recent meta-analyses provide
overall evidence of a linear dose–response relationship between
average alcohol consumption and cancers of the liver and
colorectum. Summary effect estimates for colorectal cancer are
about 11% (RR = 1.11; 95%CI: 0.90–1.38) at one drink/day
(corresponding to 10–12 g of ethanol) and 40% (RR = 1.41; 95%CI:
1.16–1.72) at more than 4–5 drinks/day [41]. The risk is higher for
drinkerswith a family history of colorectal cancer (RR = 2.80; 95%CI:
2.00–3.91 at 30 g/d compared with non-drinkers with no family
history) [42]. Overall, a slightly higher risk is reported for colon
cancer (RR = 1.16, 95%CI: 0.97–1.39) than for rectal cancer
(RR = 1.11, 95%CI: 0.97–1.29) at one drink/day [41], and the risk is
greater inmen (RR1.24; 95%CI: 1.13–1.28) than inwomen (RR 1.08;
95%CI: 1.03–1.13) at less than 1 drink/day [43], compared to never
drinkers. In both genders combined, dose–response analyses show
RRs of 1.07 (95%CI: 1.04–1.10), 1.38 (95%CI: 1.28–1.50) and 1.82
(95%CI: 1.41–2.35) at 10, 50 and 100 g/day of alcohol consumption,
respectively [43]. Associations of alcohol consumption with
hepatocellular carcinoma are generally found at high intakes [44]
with signiﬁcant increased risks of about 30–40% at consumption
levels >40 g/day [45–48]. An increased risk at low to moderate
alcohol consumption is also reported [4,47,49].
2.1.3. Neoplasms of the female breast
A positive association between alcoholic beverage consumption
and breast cancer risk is supported by more than 100 epidemio-
logical studies [2]. The risk is increased by 8% for post-menopausal
breast cancer, 9% for pre-menopausal breast cancer, and 10% for
overall breast cancer [50], per 10 g/day of ethanol.While studies on
binge drinking and cancer risk are still sparse, and a standardised
measure of exposure is lacking, the available evidence shows that
risk is increased between 33% (95%CI: 1.11–1.59, formonthly binge
drinking) [51] and 55% (95%CI: 1.07–2.26, for weekly binge
drinking) [52].
The degree of mammary development may determine a
susceptibility window for exposure to alcohol consumption, which
may be further deﬁned by hormonal status or ﬁrst full-term
pregnancy [53]. However, at present few studies have investigated
whether and to what extent the age at exposure increases cancer
risk, and the evidence is generally limited. In the Nurses’ Health
Study (NHS) II, alcohol consumption during early adulthood was
dose-dependently associatedwith an increased risk of proliferative
benign breast disease, which may lead to invasive breast cancer
later in life [54]. In contrast, a NHS prospective analysis reported
similar breast cancer risks for categories of age at alcohol exposure
of 18–40 years and >40 years (RRs = 1.21, 95%CI: 0.88–1.67 and
1.18, 95%CI: 1.03–1.34, respectively, for a daily intake of 20 g
compared to none) [51]. A large Danish cohort of post-menopausal
women also could not conﬁrm a risk difference according to the
age at which drinking was started [55].
2.2. Possible biological mechanisms
Alcoholic beverages mainly comprise ethanol and water and, in
minor percentages, other volatile and non-volatile compounds.
Ethanol is the most important carcinogen; moreover, the
metabolism of ethanol activates various pro-carcinogens present,
as well as inhaled or ingested, in alcoholic beverages. Regarding
breast cancer, ethanol most likely acts as both a weak cumulative
carcinogen and a tumour promoter of pre-existing breast cancer
cells [56]. For cancers of the oral cavity, pharynx, larynx and
oesophagus, the higher than multiplicative risk observed among
drinkers and smokers is explained by the synergistic effect of
carcinogens contained in tobacco smoke and in alcoholic beverages
which leads to mucosal hyperproliferation [57–60].
The risk of digestive tract cancers is modulated by variants of
the ethanol-metabolising enzymes, the alcohol and acetaldehyde
dehydrogenases (ADH and ALDH). The ADH1B 47Arg allele is
strongly associated with increased UADT cancer risk (RR = 3.47;
95%CI: 2.76–4.36 for the Arg/Arg genotype compared to theHis/His
genotype) [61]. The fast-metabolising ADH1C*1 variant, which is
more frequent in Caucasians [62], may increase the risk of head
and neck cancer [63,64]. The ALDH2 Lys487 allele promotes
acetaldehyde accumulation and is associated with higher risk of
oesophageal cancer [2].
Ethanol also disrupts folate metabolism regulated by methy-
lenetetrahydrofolate reductase (MTHFR) [65]; an individual’s
Table 1
Meta-analyses on alcohol consumption and cancer risk at different intakes.
Cancer ICD-10 code Reference RR (95%CI) Light drinkers# RR (95%CI) Heavy drinkers#
Oral cavity C00–C13 Turati et al. [89] 1.17 (1.01–1.35) 4.64 (3.78–5.70)
Pharynx 1.23 (0.87–1.73) 6.62 (4.72–9.29)
OP cancers Turati et al. [33] 2.55 (2.15–3.02) 5.40 (4.49–6.50)
Larynx C32 Islami et al.+ [31] 0.88 (0.71–1.08) 2.62 (2.13–3.23)
Oesophagus C15 Tramacere et al. [90] 0.92 (0.78–1.09) 1.16 (0.92–1.46)
Islami et al. [32] 1.32 (0.90–1.60) 3.35 (2.35–4.78)
Colorectal C18–C21 Fedirko et al. [43] 1.21 (1.13–1.28) 1.52 (1.27–1.81)
Liver C22 Corrao et al.+ [48] 1.19 (1.12–1.27) 1.40 (1.25–1.56)
Female breast C50 Bagnardi et al. [44] 1.05 (1.02–1.08)
Corrao et al.+ [48] 1.25 (1.20–1.29) 1.55 (1.44–1.67)
ICD-10: International Classiﬁcation of Diseases, 10th Revision [91].
# Light drinker (1drink/g or 12.5 g/day); heavy drinker (4 drinks/day or 50g/day).
+ Light drinker (25g/day); heavy drinker (50g/day) [2_TD$DIFF].
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genotype for the C677T MTHFR variant modulates the effect of
alcohol consumption on cancer risk. The CC or CT variants may
increase colorectal cancer risk among alcohol drinkers (RR = 1.87;
95%CI: 1.29–2.71) [66]. The TT variant decreasesMTHFR activity by
70% and appears to modulate risks of breast cancer, in association
with low folate intake [67,68], and of oral cancer [69], at daily
consumption of 2 drinks.
The alcohol-related increase in androgen and oestrogen levels
[70] has been suggested as a key mechanism for breast cancer’s
development. Most studies observe overall a stronger association
[(Fig._2)TD$FIG]
Fig. 2. Relationship between average daily alcohol consumption and relative risk of cancer. Plots of the relative risk functions for all cancers causally associated with alcohol
consumption. The relationship between alcohol consumption and cancer risk is monotonic and without a threshold. From Corrao et al. [48] http://dx.doi.org/10.1016/j.
ypmed.2003.11.027 PMID:15066364.
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with the most common oestrogen-receptor-positive (ER+) and/or
progesterone-receptor-positive (PR+)markers comparedwith ER
and/or PR breast tumours, for the highest versus the lowest
alcohol consumption group [71–73]. A meta-analysis showed that
for each additional drink, breast cancer risk increases by 12%
among ER+ subjects, by 11% among ER+PR+ subjects, by 15% among
ER+PR subjects, and by 7% for all ER subjects, and no association
was apparent with ER/PRor ER/PR+ tumours when considered
separately [74].
Other ethanol-mediated toxic effects associated with cancer
development are cirrhosis of the liver and gastro-oesophageal
reﬂux disease, which leads to hyperproliferation of the oesopha-
geal mucosa. Also, ethanol-associated immune suppression may
facilitate tumour cell spread [65].
3. Justiﬁcation for recommendation
The consumption of alcoholic beverages is causally associated
with cancers of the oral cavity, pharynx, larynx, oesophagus, liver,
colorectum and female breast. Risk estimates of alcohol-related
cancer incidence and mortality emphasise a dose-dependent
relationship that does not vary by beverage type and does not
show a threshold of intake, since the adverse effect is observed
even at consumption of less than one alcoholic drink per day
[12,75]. Ethanol carcinogenesis may not uniformly target tissues
and may depend on drinking patterns and timing of exposure, as
based on observed differences in cancer risk across organ sites.
Taking all these issues into account, the ECAC has developed the
following recommendation:
‘‘If you drink alcohol of any type, limit your intake. Not drinking
alcohol is better for cancer prevention.’’
3.1. Alcohol-attributable burden of disease
Worldwide, alcohol consumption is the second leading risk
factor after tobacco in terms of morbidity, and it accounts for a
signiﬁcant number of deaths, particularly in high-income coun-
tries. In Europe, alcohol is the third leading risk factor for disease
andmortality after tobacco and high blood pressure [76]. Alcohol is
causally associated with about 60 types of disease, including heart
disease, stroke and vascular diseases, as well as liver cirrhosis and
cancer. Fetal exposure to alcohol strongly increases the risk of birth
defects and intellectual impairments. Alcohol-use disorders (e.g.,
acute alcohol intoxication, alcohol-dependence syndrome) ac-
count for a signiﬁcant share of total morbidity, particularly among
men (44.5%) [1]. Alcohol also contributes to death and disability
through accidents and injuries, assault, violence, homicide and
suicide.
In the EU in 2004, almost 95,000 men and more than 25,000
women, aged 15–64, died prematurely of alcohol-attributable
causes. This means that one in seven male and one in 13 female
premature deaths in this age category were caused by alcohol
[76]. In men in 2004, approximately two in ﬁve deaths were due to
liver cirrhosis, one in three to injuries, and one in ﬁve (15.9%) to
cancer. In women, more than two thirds of alcohol-attributable
deaths arose from liver cirrhosis and cancer (30.7%; the largest
proportion of which, 21%, involves breast cancer), with cardiovas-
cular disease other than ischaemic heart disease as a distant third
cause.
Almost 90% of the burden of disease attributable to alcohol is
caused by heavy drinking, both regular and irregular. This has
important implications for prevention and alcohol policy: any
measure which aims to successfully reduce alcohol-attributable
harm has to involve cutting down regular and irregular heavy
drinking occasions.
3.2. Public policies on alcohol taxation as measures of prevention
Negative health effects and social harm caused by detrimental
alcohol consumption can be reduced through effective prevention
strategies. In 1979, the World Health Assembly called upon World
Health Organization (WHO) member states to develop and adopt
appropriate legislation and measures to tackle alcohol misuse
[77]. Such efforts culminatedwith the endorsement, in 2010, of the
global strategy on the harmful use of alcohol [78] that supports ten
target areas for national actions, including: health sector response,
community actions, drink-driving policies, limitation of the
availability of alcohol, action on marketing and pricing policies,
reducing the negative consequences of intoxication and reducing
the public health effect of illegally and informally produced
alcohol. Based on four key criteria (namely effectiveness,
affordability, efﬁciency and acceptability/feasibility), the WHO
has more recently identiﬁed restricted access to retailed alcohol,
limitation of alcohol advertising, and taxes on alcohol as the best-
performing interventions to tackle harmful alcohol use [79]. Both
the enforcement of drink-driving laws and brief advice for
excessive drinkers are valuable interventions, although their
efﬁciency in some settings may be less attractive.
In particular, alcohol prices – and consequently affordability –
are a strong determinant of alcohol consumption and can be
altered by using taxes or direct price controls, including minimum
price policies [80]. However, public policies on alcohol taxation are
not always homogeneous across the EU. Countrieswith stricter and
more comprehensive alcohol policies generally have lower levels
of alcohol consumption. Observational studies suggest that the
effects of taxation would be larger for moderate than heavy
drinkers [81], women [82], and young consumers [83]. On average,
a 10% increase in the price of alcohol is correlated with a 4.4%
decrease in consumption, with some variability depending on the
type of alcoholic beverage [84]. Sadly, between 1996 and
2004 affordability has increased by 50% or more in Estonia, the
United Kingdom, Czech Republic, Finland and Ireland, and by a
smaller amount in Portugal, Spain, Denmark, Sweden, France,
Austria, the Netherlands, Greece, Germany, Poland and Belgium–in
particular for young people [85]. Time-series analyses in Canada
(British Columbia) showed that a 10% increase in the minimum
price for alcohol reduces the consumption of spirits by 6.8%, of
wine by 8.9%, of alcopops (ﬂavoured, often sweet, alcoholic
beverages) by 13.9%, and of beer by 1.5% [86]. The most common
[(Fig._3)TD$FIG]
Fig. 3. Estimated relative risk (RR) for the interaction between tobacco smoking and
alcohol drinking on cancers of the upper respiratory tract (reference category,
risk = 1). Combined exposure to alcohol drinking and tobacco smoking increases the
risk of upper digestive and respiratory tract neoplasms in a supra-multiplicative
manner. From P. Boyle, P. Autier, H. Bartelink, et al. European Code Against Cancer
and scientiﬁc justiﬁcation: third version (2003) Annals of Oncology 2003, 14: 973–
1005, by permission of Oxford University Press [7].
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approach in European countries is based on a combination of
excise duty and value-added taxes, which should account for
potential effects of the type of beverage consumed. As an example,
the introduction of a tax on alcopops in Germany simply shifted
consumption from spirit-based to beer-based beverages [87].
4. Conclusion
Worldwide, alcohol consumption is the second leading risk
factor in terms of morbidity, and it accounts for a signiﬁcant
number of deaths, particularly in high-income countries. In
Europe, it has been estimated that about 10% (95%CI: 7–13%) of
all cancer cases in men and 3% (95%CI: 1–5%) of all cancer cases in
women are attributable to alcohol consumption [12]. There is
strong evidence that people can reduce their risk of cancer by
limiting or cutting their consumption of alcoholic drinks. Overall,
in European populations the risk of cancer in men who consume
less than two alcoholic drinks (less than 20 g of pure alcohol) per
day and inwomenwho consume less than one alcoholic drink (less
than 10 g of pure alcohol) per day is 6% lower (hazard ratio = 0.94;
95%CI: 0.90–0.96) than that in people with higher alcohol intakes
[88]. On average, reducing the consumption from four or more to
one or less alcoholic drinks per day may reduce the risk of liver
cancer by 21% [48], the risk of colorectal cancer by 31% [43], and
the risk of female breast cancer by 30% [48]. The WHO have stated
clearly that increasing price, reducing availability and banning
advertising are the most effective policy measures that should be
implemented at the European level in order to decrease the
alcohol-related burden of disease [4_TD$DIFF].
European Code Against Cancer.:
EUROPEAN CODE AGAINST CANCER:
12 ways to reduce your cancer risk
1. Do not smoke. Do not use any form of tobacco
2.Make your home smoke free. Support smoke-free policies in
your workplace
3. Take action to be a healthy body weight
4. Be physically active in everyday life. Limit the time you
spend sitting
5. Have a healthy diet:
 Eat plenty of whole grains, pulses, vegetables and fruits
 Limit high-calorie foods (foods high in sugar or fat) and
avoid sugary drinks
 Avoid processed meat; limit red meat and foods high in
salt
6. If you drink alcohol of any type, limit your intake. Not
drinking alcohol is better for cancer prevention
7. Avoid too much sun, especially for children. Use sun pro-
tection. Do not use sunbeds
8. In the workplace, protect yourself against cancer-causing
substances by following health and safety instructions
9. Find out if you are exposed to radiation from naturally high
radon levels in your home; take action to reduce high radon
levels
10. For women:
 Breastfeeding reduces themother’s cancer risk. If you can,
breastfeed your baby
 Hormone replacement therapy (HRT) increases the risk of
certain cancers. Limit use of HRT
11. Ensure your children take part in vaccination programmes
for:
 Hepatitis B (for newborns)
 Human papillomavirus (HPV) (for girls)
12. Take part in organised cancer screening programmes for:
 Bowel cancer (men and women)
 Breast cancer (women)
 Cervical cancer (women)
The European Code Against Cancer focuses on actions that
individual citizens can take to help prevent cancer. Successful
cancer prevention requires these individual actions to be
supported by governmental policies and actions.
The resulting recommendation of the 4th edition of the ECAC
targeted to individuals is to limit or cut the consumption of
alcoholic beverages.
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